Aethlon medical announces activation of royal adelaide hospital to begin patient screening and enrollment in hemopurifier® cancer trial

Aethlon's trial is a safety, feasibility, and dose finding study of the hemopurifier® in patients with solid tumors not responding to anti-pd-1 antibodies san diego , sept. 16, 2024 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that the cancer clinical trial unit at royal adelaide hospital was activated on september 10, 2024 to begin screening and enrolling patients in its safety, feasibility and dose-finding clinical trial of the hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-pd-1 monotherapy treatment, such as keytruda® (pembrolizumab) or opdivo® (nivolumab) (aemd-2022-06 hemopurifier study).
AEMD Ratings Summary
AEMD Quant Ranking